Literature DB >> 15825040

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.

Sonia Rodriguez-Novoa1, Pablo Barreiro, Ana Rendón, Inmaculada Jiménez-Nacher, Juan González-Lahoz, Vincent Soriano.   

Abstract

We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus-positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15825040     DOI: 10.1086/429327

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  53 in total

1.  Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

Authors:  Salvador Cabrera Figueroa; Alicia Iglesias Gómez; Almudena Sánchez Martín; María de la Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé; Miguel Cordero Sánchez
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  PharmGKB summary: very important pharmacogene information for CYP2B6.

Authors:  Caroline F Thorn; Jatinder K Lamba; Vishal Lamba; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-08       Impact factor: 2.089

3.  The impact of host pharmacogenetics on antiretroviral drug disposition.

Authors:  Andrew Owen
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 4.  Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Authors:  Margalida Rotger; Chantal Csajka; Amalio Telenti
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

5.  Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.

Authors:  Xia Liu; Qing Ma; Yan Zhao; Weiwei Mu; Xin Sun; Yuewu Cheng; Huiping Zhang; Ye Ma; Fujie Zhang
Journal:  Pharmacotherapy       Date:  2017-09-03       Impact factor: 4.705

Review 6.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

7.  Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

Authors:  David J Back; Andrew Owen; Saye H Khoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Efavirenz in the therapy of HIV infection.

Authors:  Natella Y Rakhmanina; John N van den Anker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

9.  Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.

Authors:  Sofia A Pereira; Umbelina Caixas; Teresa Branco; Isabel Germano; Fátima Lampreia; Ana L Papoila; Emília C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2008-06-09       Impact factor: 4.335

Review 10.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.